PRESS RELEASE published on 04/02/2025 at 18:00, 11 months 20 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC waaruit blijkt verkoop van aandelen onder drempel. Meer informatie op www.oxurion.com Transparantiekennisgeving Oxurion NV Oftalmologische Therapieën Biofarmaceutisch Bedrijf Atlas Special Opportunities II LLC
PRESS RELEASE published on 04/02/2025 at 18:00, 11 months 20 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 11 months 26 days ago Oxurion reçoit une notification de transparence ajustée Actionnariat Notification De Transparence Oxurion Atlas Special Opportunities II Bourse De Bruxelles
BRIEF published on 03/27/2025 at 18:05, 11 months 26 days ago Oxurion receives adjusted transparency notification Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange
PRESS RELEASE published on 03/27/2025 at 18:00, 11 months 26 days ago Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities II LLC, waardoor zij onder de drempel (5%) komen. Meer informatie beschikbaar op www.oxurion.com Transparantiekennisgeving Oxurion NV Netvliesaandoeningen Biofarmaceutisch Bedrijf Atlas Special Opportunities II LLC
PRESS RELEASE published on 03/27/2025 at 18:00, 11 months 26 days ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received an amended transparency notification from Atlas Special Opportunities II, LLC regarding the sale of voting securities. This press release replaces the one from March 18, 2025 Transparency Notification Euronext Brussels Oxurion NV Retinal Disease Therapies Atlas Special Opportunities II
BRIEF published on 03/24/2025 at 18:05, 11 months 29 days ago Oxurion Announces Capital Increase Following Convertible Bond Conversion Convertible Bonds Capital Increase Atlas Special Opportunities Ophthalmic Therapies Oxurion
BRIEF published on 03/24/2025 at 18:05, 11 months 29 days ago Oxurion annonce une augmentation de capital suite à la conversion d'obligations convertibles Obligations Convertibles Augmentation De Capital Thérapies Ophtalmiques Oxurion Opportunités Spéciales Atlas
PRESS RELEASE published on 03/24/2025 at 18:00, 11 months 29 days ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts bonds in Oxurion, resulting in EUR 150,000 capital increase. Oxurion focuses on developing therapeutics for vision care Capital Increase Therapeutics Vision Care Atlas Special Opportunities LLC Oxurion
PRESS RELEASE published on 03/24/2025 at 18:00, 11 months 29 days ago Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie Atlas Special Opportunities, LLC converte 6 obligaties in Oxurion, resulterend in EUR 150.000 kapitaalverhoging. Investering in innovatieve geneesmiddelen voor ouderen Euronext Brussel Kapitaalverhoging Atlas Special Opportunities Oxurion Innovatieve Geneesmiddelen
Published on 03/23/2026 at 14:05, 1 hour 59 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 2 hours 4 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 2 hours 59 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 3 hours 32 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 3 hours 34 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 15:05, 58 minutes ago Heidrick & Struggles Launches Heidrick Immersive, an AI-Enhanced Platform for Observing Leadership in Motion
Published on 03/23/2026 at 14:41, 1 hour 22 minutes ago CEWE increases dividend for 17 consecutive years
Published on 03/23/2026 at 14:30, 1 hour 33 minutes ago Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Published on 03/23/2026 at 14:30, 1 hour 33 minutes ago Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach
Published on 03/23/2026 at 14:24, 1 hour 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 03/23/2026 at 08:10, 7 hours 54 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 21 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 21 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 21 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 21 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
